Teva Pharmaceutical Indus Analyst Ratings
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $24
Argus Upgrades Teva to Buy, Cites Recent Drug Approvals
Goldman Sachs Downgrades Riskified to Sell, Announces $6 Price Target
Riskified Analyst Ratings
Wolfe Research Initiates Coverage On Monday.Com With Outperform Rating, Announces Price Target of $300
Monday.Com Analyst Ratings
Buy Rating Affirmed: Monday.com's Growth and Innovation in the SaaS Sector
Wells Fargo Reaffirms Their Hold Rating on WalkMe (WKME)
Keybanc Maintains Overweight on Monday.Com, Lowers Price Target to $270
Monday.Com Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Monday.Com Analyst Ratings
Barclays Initiates Monday.com at Overweight With $275 Price Target
Semi Stocks Undergo Upgrades, Price Target Hikes on AI Demand: B Riley
Camtek Analyst Ratings
B. Riley Raises Price Target on Camtek to $150 From $110, Maintains Buy Rating
Pagaya Techs Analyst Ratings
Keefe, Bruyette & Woods Initiates Coverage On Pagaya Techs With Outperform Rating, Announces Price Target of $23